The U.S. Food and Drug Administration (FDA) approved a supplemental application for Keytruda (pembrolizumab) on February 4, 2022. This significant regulatory action, designated as BLA 125514 S-95, expands the drug's approved uses based on demonstrated efficacy. While the specific new indication or patient population for this approval was not detailed in the primary source document, it represents an important update to the prescribing information for this widely used immunotherapy.
Background
Pembrolizumab, marketed as Keytruda by Merck Sharp Dohme, is an established therapeutic agent in oncology. It is known for its role in treating various cancers by targeting the PD-1 pathway. Supplemental applications for existing drugs like Keytruda are typically submitted to the FDA to expand their approved indications, modify dosing regimens, or update safety information. This particular supplemental approval, categorized under efficacy, signifies that new clinical data supported an additional benefit for a specific patient group or disease context, leading to an expansion of the drug's label.
What this means
This supplemental approval for Keytruda (pembrolizumab) has direct implications for clinical practice, allowing healthcare providers to utilize the drug for an expanded set of patients or conditions. Although the precise new indication is not specified in the provided data, such approvals are granted after the FDA reviews comprehensive clinical trial data demonstrating that the drug is safe and effective for the new proposed use. Clinicians should consult the updated prescribing information and official label for Keytruda to understand the full scope of this expanded approval, including any new patient populations, specific disease types, or treatment lines. This ensures appropriate patient selection and management in accordance with the latest regulatory guidance.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) on February 4, 2022. The details of the approval for supplemental application BLA 125514 S-95 are publicly accessible on the FDA's accessdata.fda.gov website, which serves as a primary resource for regulatory actions concerning approved drug products.